In addition to restating its 2023 annual report, Discover also amended its quarterly reports from the first and second quarters of 2024 and filed a previously delayed report covering its third quarter
Week 12 assessment, if under 5% weight loss, discuss dose escalation
My vocation is to help those with eczema and digestive issues, because I have suffered with these interlinked conditions since I was 6 months old, and I truly know what it is like to experience these debilitating conditions
A Randomized Study of Pretransplant Conditioning Therapy for AML/MDS with Fludarabine Clofarabine and Once Daily IV Busulfan with Allogeneic Hematopoietic Transplantation for AML and MDS
Reddy NM, Kleeberger SR, Bream JH, Fallon PG, Kensler TW, Yamamoto M, et al